Lantern Pharma insider amends options, replaces strikes with $5.04 grants
Rhea-AI Filing Summary
Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), filed a Form 4 reporting amendments to previously granted stock options. The filing shows two option amendments: a June 15, 2020 option was cancelled and replaced with a $5.04 exercise-price option covering 52,200 shares exercisable through 06/14/2030; a October 29, 2021 option was cancelled and replaced with a $5.04 exercise-price option covering 17,400 shares exercisable through 10/28/2031. After the replacements, Mr. Bhatia beneficially owns 52,200 and 17,400 underlying common shares for the respective options.
Positive
- Replacement options were granted rather than immediate option exercises or stock sales, preserving insider alignment with future equity-based incentives
- Vesting schedules reference original vesting (no acceleration disclosed), indicating continued standard vesting terms
Negative
- Exercise price reduction occurred (replacement strike $5.04), which could increase potential future dilution relative to prior strikes
- Cancellation of original options was required to effect the repricing, indicating a material amendment to insider compensation
Insights
TL;DR: Insider option exercise prices were reduced via replacement grants totaling 69,600 underlying shares, maintaining the reporting person s holder.
The Form 4 documents two option amendments where previously granted options were cancelled and replaced with options priced at $5.04 each covering 52,200 and 17,400 shares respectively, with expirations of 06/14/2030 and 10/28/2031. These transactions do not record any immediate sale or acquisition of common stock; they report derivative restructuring. For investors, this is a governance/compensation event affecting potential future dilution and insider incentives but contains no cash proceeds or reported exercises.
TL;DR: The company amended outstanding options to lower exercise prices, replacing old options with new $5.04 strike options for the same share counts.
The filing explicitly states the old options were cancelled and replacement options granted to effect a reduction in exercise price. Vesting schedules referenced are the original schedules from 06/15/2020 and 11/29/2021, indicating no new vesting acceleration disclosed. This is a compensation adjustment that should be disclosed to shareholders; it may warrant review of board approvals and disclosure on rationale, but the Form 4 contains only the transactional facts.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 17,400 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 17,400 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 52,200 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 52,200 | $0.00 | -- |
Footnotes (1)
- The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date). The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021.
